Neolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review
Ageing Research Reviews · 2024-08 · 99 · 102398
DOI: 10.1016/j.arr.2024.102398 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Ageing Research Reviews, 2024-08. Verfasst von Na Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: lin…. Hauptthemen laut MEDLINE: Alzheimer Disease, Lignans, Magnolia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 106 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Magnolia officinalis, a traditional herbal medicine widely used in clinical practice, exerts antibacterial, anti-tumor, anti-inflammatory, antioxidant, and anti-aging activities. Neolignans are the main active ingredients of M. officinalis and exert a wide range of pharmacological effects, including anti-Alzheimer's disease (AD) activity. OBJECTIVE: To summarize the published data on the therapeutic effect and mechanism of neolignans on AD in vivo and in vitro. METHODS: PubMed, Web of Science, Google Scholar, and Scopus were systematically reviewed (up to March 1, 2024) for pre-clinical studies. RESULTS: M. officinalis-derived neolignans (honokiol, magnolol, 4-O-methylhonokiol, and obovatol) alleviated behavioral abnormalities, including learning and cognitive impairments, in AD animal models. Mechanistically, neolignans inhibited Aβ generation or aggregation, neuroinflammation, and acetylcholinesterase activity; promoted microglial phagocytosis and anti-oxidative stress; alleviated mitochondrial dysfunction and energy metabolism, as well as anti-cholinergic deficiency; and regulated intestinal flora. Furthermore, neolignans may achieve neuroprotection by regulating different molecular pathways, including the NF-κB, ERK, AMPK/mTOR/ULK1, and cAMP/PKA/CREB pathways. CONCLUSIONS: Neolignans exert anti-AD effects through multiple mechanisms and pathways. However, the exact targets, pharmacokinetics, safety, and clinical efficacy in patients with AD need further investigation in multi-center clinical case-control studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: lin3@sj-hospital.org.
- Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: liangyy@sj-hospital.org.
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: cmu_lijuanzhang@163.com.
- Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: xucl@sj-hospital.org.
- Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, PR China. Electronic address: wanglin906731@163.com.
Zitieren
APA
Li, N., Liang, Y., Zhang, L., Xu, C., & Wang, L. (2024). Neolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review. Ageing Research Reviews, 99, 102398. https://doi.org/10.1016/j.arr.2024.102398
Vancouver
Li N, Liang Y, Zhang L, Xu C, Wang L. Neolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review. Ageing Research Reviews. 2024;99:102398. doi:10.1016/j.arr.2024.102398
BibTeX
@article{Li2024,
author = {Li, Na and Liang, Yuanyuan and Zhang, Lijuan and Xu, Changlu and Wang, Lin},
title = {Neolignans in Magnolia officinalis as natural anti-Alzheimer’s disease agents: A systematic review},
journal = {Ageing Research Reviews},
year = {2024},
volume = {99},
pages = {102398},
doi = {10.1016/j.arr.2024.102398}
}
EUVIMED